Elin Trampe CEO

Elin holds a Master of Science in Industrial Engineering and Management from Linköping University. She has held several managerial and international roles in various types of companies and industries, including the global companies Mondelz International and GE Global Operations as well as the pharmaceutical company Oasmia Pharmaceutical AB, where Elin had the role as Chief Technical Officer before joining Dicot. Elin has extensive experience in business development, strategic international partnerships, operational excellence, and product development.

Employed in 2021 as COO and Deputy CEO. Assumed the role as CEO in 2022.

Holdings: 1,005,000 shares, and 50,000 warrants in incentive programs.

Björn Petersson CFO

Björn Petersson has over 20 years of experience as Chief Financial Officer and from other leading roles. He has broad expertise in business administration, financing and business management and has been engaged in several different industries, including Life Science, and in several companies listed on the stock market. Björn acted CFO at Flat Capital's IPO in 2021 and he has studied Business Administration and Financial Control at Stockholm University and the Executive Leadership Program at SSE Executive Education.

Assumed the role in 2022.

Holdings: 168,150 shares (owned via company).

Charlotta Gauffin CSO

Charlotta has more than 20 years of experience in the pharmaceutical industry from for example Medivir, Biovitrum and Galderma, of which more than 15 years within clinical development. She has had roles such as Clinical Project Manager, Program Director and Head of Clinical Operations. Charlotta also has experience of medical writing and development of clinical and regulatory documents. Charlotta has a PhD in organic chemistry from Uppsala University.

Assumed the role in 2022.

Holdings: 579,032 shares.

Mats Silvander CTO

Mats has over 20 years of industry experience as Director of Operations, CTO, Vice President Product Development and Quality Manager in areas such as pharmaceutical manufacturing, supplier management, patent work, and building and developing processes and effective teams. Mats has a PhD in Physical Chemistry and has worked for, among others, Novavax, BioGaia, Paragon Nordic, and Quinnova Pharmaceuticals, Inc.

Assumed the role in 2023.

Holdings: 501,297 shares.